Hims closes its compounded GLP-1 programme to new patients
Following a settlement with Novo Nordisk, one of the largest platforms exits compounded semaglutide.
Following a settlement with Novo Nordisk, one of the largest platforms exits compounded semaglutide.
All-in monthly cost at 10 mg
Hims closed its compounded GLP-1 programme to new patients in March 2026 following a settlement with Novo Nordisk, continuing to offer brand-name products billed separately from membership.
It is part of a pattern rather than an isolated exit, and it is why comparisons written before spring 2026 should be treated as historical.
For patients the consequence is consolidation: compounded access has moved toward smaller operators.
What this changes for what you pay
Most developments in this category move one of three things: the price of the branded product, which programmes are operating, or what may lawfully be compounded. Very few change the prescription requirement, the pharmacy licensing framework or the clinical review behind a prescription.
The cheapest verified compounded route we track currently sits at $215 a month all-in at a 10 mg maintenance dose, about $2,580 for a first year. Where a development moves that figure, our tables move with it on the next build.
How to verify this yourself
Regulatory claims should be checked against the agency rather than against coverage of the agency. FDA publishes warning letters searchable by company name, a shortage database, and its compounding pages. Trial claims should be checked against the registry entry rather than a press release.
Every source behind this item is linked below, and where a story is still moving we say so rather than implying it is settled.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.